NASDAQ
0.96USD
-0.02 (-1.87%)
We have scored 6 news catalysts on Codexis, Inc. (CDXS) over the past 12 months. The biggest single-day move next to one of them came Jul 26, 2026, when CDXS closed −25.6%: “Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade)”. Coverage across the window leans positive (average ticker sentiment +0.30). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
104.9M
P/E
—
EPS
—
Beta
2.39
52W range
0.9-2.98
Day range
0.90–0.97
Open
0.96
Prev close
0.98
Volume
1M
Avg volume
1M
Dividend
0.00
IPO
2010-04-22
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Codexis, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CDXS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
